Hyperfine Revenue Misses, Yet Stock Plunges 19.51% MTD

Hyperfine reported fiscal 2026 Q2 earnings on August 6, 2026. The company’s revenue of $3.90 million missed consensus estimates of $4.3 million, while GAAP EPS of -$0.09 remained in line with expectations. Management reaffirmed full-year 2026 revenue guidance of $20 million to $22 million, indicating no change to previous outlooks despite the quarterly miss.

Revenue

The total revenue of Hyperfine increased by 44.8% to $3.90 million in 2026 Q2, up from $2.70 million in 2025 Q2. Device sales contributed $3.17 million to this total, while service revenue accounted for $734,000, bringing the total sales figure to $3.90 million.

Earnings/Net Income

Hyperfine narrowed losses to $0.09 per share in 2026 Q2 from a loss of $0.12 per share in 2025 Q2 (25.0% improvement). Meanwhile, the company's net loss widened to $-9.30 million in 2026 Q2, representing a 0.8% increase from the $-9.22 million loss recorded in 2025 Q2. The Company has sustained losses for 6 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. Although the per-share loss improved, the widening net loss indicates that higher revenues did not fully offset fixed cost pressures, signaling mixed operational efficiency.

Price Action

The stock price of Hyperfine has edged down 0.01% during the latest trading day, has climbed 5.80% during the most recent full trading week, and has plummeted 19.51% month-to-date.

Post-Earnings Price Action Review

Hyperfine's recent stock performance reflects significant volatility, with the share price plummeting 19.51% month-to-date despite a modest 5.80% gain over the most recent full trading week and a negligible 0.01% decline on the latest trading day. In evaluating a "buy the beat" strategy, backtesting using the most recent earnings window shows a 30-day post-earnings return of -12.5%, which is not supportive for this setup. This weak outcome suggests that the market did not reward the earnings report with sustained upside, highlighting the risks of simple post-earnings hold strategies for this asset.

CEO Commentary

Maria Sainz, President and Chief Executive Officer, reported strong Q2 execution with revenue reaching $3.9 million, driven by the Model 2 Swoop system launch and expanded adoption across hospitals, offices, and international markets. Strategic priorities include leveraging AI capabilities, achieving FDA submission for contrast labeling by year-end, and scaling enterprise health system engagement. Sainz highlighted high utilization in emergency departments and growing neurology office demand, supported by clinical evidence and ease of use. She expressed optimism regarding the diversified commercial profile, noting improved gross margins and reduced cash burn. Leadership outlook is confident, emphasizing a stronger balance sheet, identifiable growth catalysts, and the transition from proof points to broader commercial scale across multiple verticals.

Guidance

Hyperfine reaffirms full-year 2026 revenue guidance of $20 million to $22 million, representing approximately 55% year-over-year growth at the midpoint. The company expects gross margins to remain within the 50% to 55% range, supported by four consecutive quarters exceeding 50% and disciplined commercial execution. Full-year total cash burn is projected at $26 million to $28 million, indicating a roughly 10% year-over-year decline. Management cites identifiable drivers for the second-half outlook, including continued Model 2 adoption, hospital capital planning cycles, office market expansion, and international rollout execution. These financial targets position the company to extend its cash runway into 2028 while maintaining financial flexibility for ongoing commercial growth and product development initiatives.

Additional News

Hyperfine recently presented at the Jefferies Global Healthcare Conference 2026, where management reiterated its commitment to achieving $20 million to $22 million in 2026 revenue while maintaining gross margins between 50% and 55%. The company highlighted its progress toward an FDA submission for expanded contrast labeling, with 75% of enrollment already complete. Analysts have set price targets ranging from $2 to $2.50, contrasting with the current trading price near $1. Additionally, insider trading activity has seen five sales by Chief Operating Officer Thomas Teisseyre over the past six months, with no purchases recorded. The company also noted a 15% drop in R&D spending following 2025 restructuring, while SG&A rose only 3% year-over-year, demonstrating cost discipline amid its commercial expansion efforts.